Diagnosis and treatment system for "reward deficiency syndrome" (RDS) and related behaviors

a reward deficiency syndrome and treatment system technology, applied in the direction of biocide, peptide/protein ingredients, carrier-bound antigen/hapten ingredients, etc., can solve the problem of insufficient dopaminergic activity, self-sustaining abnormal craving behavior in both animals and humans, and endure tremendous pain and hardship

Inactive Publication Date: 2006-04-13
SYNAPTAMINE INC
View PDF0 Cites 29 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0150] c) a tryptophan concentration enhancing amount of chromium picolinate or chromium nicotinate, the amount of said substance and said neurotransmitter precursor and said chromium compound being effective in reducing the subject's RDS behaviors.
[0151] An important aspect of the present invention, a tryptophan concentration-enhancing amount of chromium nicotinate or chromium picolinate may be present. This combination now being effective in preventing or reducing a subjects unwanted weight or other RDS behaviors, such as attention deficits disorder, intentional processing or memory deficiency. Further RDS behaviors may include any in the group existing of SUD, Obesity, Smoking, Tourettes Syndrome, ADHD, Schizoid / Avoidant Behavior, Aggression, Posttraumatic stress syndrome, PMS or tobacco use. In certain aspects, composition of the present invention may include a daily dietary composition comprising 32 to 10,000 mg DL-phenylalanine, 5 to 5,000 mg L-tryptophan, 3 to 30,000 mg L-glutamine, and the composition further comprises 1-300 mg pyridoxal-5′-phosphate. When the term excess weight is involved, it is understood that this indicates obesity. In a preferred aspect, the kit involves a composition that comprises a daily dietary consumption of about 460 mg DL-phenylalanine, 25 mg L-tryptophan, 25 mg L-glutamine, and the mixture further comprises 5 mg pyridoxal-5′-phosphate. Allelic analysis may be confirmed by observation of a family history of certain RDS behaviors, this involving or confirming an improved likelihood for successful treatment by consumption of the subject composition in the kit. Various other RDS behaviors such as binge eating and cravings for various sensations are also a subject of the present invention.

Problems solved by technology

The overall effect is inadequate Dopaminergic Activity in the Reward Center of the Brain.
Also, it has been found that the genetic abnormality is associated with aggressive behavior which also stimulates the brain's use of Dopamine.
They would even endure tremendous pain and hardship for an opportunity to press the lever.
Genetic anomalies, long-term continuing stress, or long-term abuse of substances can lead to a self-sustaining pattern of abnormal craving behavior in both animals and humans.
Compulsive diseases include pathological gambling and excessive sexual activity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnosis and treatment system for "reward deficiency syndrome" (RDS) and related behaviors

Examples

Experimental program
Comparison scheme
Effect test

example i

Composition A

[0209] The invention includes the intravenous administration of a new class of anti-craving compositions provided by substances which inhibit the breakdown of endogenous substances such as enkephalins and endorphins. Specifically, D-phenylalanine, DL-phenylalanine, D-Leucine, DL-Leucine, and hydocinnamic acid, each in an intravenous solution in sufficient concentration to bring about enkephalinase inhibition which would significantly lower alcohol intake in animals and humans. The anti-alcohol desire effect has been observed in animals genetically prone to choose alcohol over water, but this effect has never been observed via the intravenous route. The inventors believe that the intravenous route would be advantageous since the dose needed would be much less than what is required by the oral dose. In a series of experiments the exact dose will be determined in both humans and animals to at least reduce alcohol or drug intake.

[0210] In this invention only and not in li...

example ii

Composition B

[0214] The inventor believes that the substrate for RDS behaviors is mediated by regions in the brain's “pleasure center” or “reward centers” which are high in a number of neurotransmitters including dopamine. These regions include the dopamine-containing nucleus accumbens, and its projection to limbic structures and frontal cortex. It has been observed that if dopamine projections to limbic and cortical areas are lessioned the self-administration of psychoactive drugs which release dopamine (e.g. alcohol, cocaine, heroin, nicotine etc) by animals are greatly reduced. Moreover, selective dopamine receptor antagonists, like haloperidol, atenuate or block alcohol and cocaine self-administration in animals. Similarly, in humans, pretreatment with dopamine receptor antagonits will block stimulant-induced “euphoria”. Additionally, dopamine receptor agonists (e.g. bromocryptine, apomorphine etc) have rewarding actions. These and other studies suggest that the lack of “reward...

example iii

Composition C

In this composition the inventors are including a tryptophan concentration enhancing amount of all salts and chelates of chromium (e.g. picolinate, nicotinate, ablion chelate etc.).

Background on Chromium

[0231] Body cells need chromium to keep insulin working properly as well as a host of other important biological actions. Scientists agree, that insulin directs the movement of digested food into the body's cells and affects how that food is used. When insulin doesn't act as intended, blood glucose and fat aren't stored and used properly. This malfunction leads to obesity, heart disease, or diabetes.

[0232] Our diets contain little chromium, and what chromium we do eat is often in a form that is difficult for the body to absorb. Therefore, chromium must be combined with a substance that will allow this substance to enter the bloodstream. A number of forms include picolinate, polynicotinate as well as Ablion chelate. Dozens of studies have proven that chromium, in th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
areaaaaaaaaaaa
stress ratesaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a kit and an intravenously administrable preparation, both with a signal transmitter precursor, an enhancer of precursor uptake, and an inhibitor of neurotransmitter reuptake or signal transmitter catabolism. The kit also contains an appropriate swab for obtaining oral cells suitable for allelic analysis. The intravenous formulation contains similar materials and, in some cases, ethanol. Either the kit composition or the intravenous formulation may be used as guided by a subjects allelic analysis. Collections of particular alleles, especially those relating to neural system are comprehensible in terms of likelihood of success in the administration of an intraveinous formulation or ingestion of components of the subject kit.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of and is a divisional application of U.S. application Ser. No. 09 / 632,838, filed on Aug. 4, 2000.BACKGROUND OF THE INVENTION [0002] The following pending applications are hereby incorporated by reference: Ser. Nos. 09 / 481,426 and 09 / 069,886 and 09 / 356,266 and 09 / 423,040 and PCT US 98 / 08684. [0003] SynerGene NutraLife Essentials, which is a division of CyberPharm Corporation, is a new line of patent protected nutraceuticals and neutraceuticals. All products in the SynerGene line provide high quality nutrients consisting of amino acids, trace minerals, vitamins, minerals, and herbals. When combined into numerous blends they have demonstrable therapeutic health benefits. The uniqueness of this particular line is that each product is specifically formulated to achieve synergistic activity from the active ingredient which has been shown by specific studies as well as functional combinations which have not...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/555A61K31/198A61K31/045A01N37/42A61K39/385C12Q1/68
CPCA61K31/045A61K31/198A61K31/555A61K45/06A61K2300/00
Inventor BLUM, KENNETH
Owner SYNAPTAMINE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap